Marc Beer is a graduate from Miami University where he earned a BS; upon graduation he devoted himself to work in various fields including pharmaceuticals, biotech technology, diagnostics, devices among others. Marc Beer is the founding chairman of the board of directors at the Compensation Committee for the Good Start Genetics company, and NASDAQ: NERV. He has also enrolled at the Miami University Business advisory council to share his insight on various businesses related to the health sector, and even the Notre Dame Research advisory committee. While working at Genzyme, Marc Beer served multiple roles regarding sales and marketing of the company’s products as well as managing the Abbott Laboratories.
Later Marc Beer joined the ViaCell company to serve as the CEO; the company specialized in collecting, preserving and developing various umbilical cord blood stem cells. Marc Beer served for almost seven years, and at the end of his reign the company had employed more than 300 employees to manage its operations; he ensured ViaCell traded publicly in 2005. Later Marc Beer in partnership with MD, Yolanda Loire and Ramon Iglesias founded Renovia company with the aim of establishing various series of healthcare venture capital funds. Renovia company found Leva Product which is a significant treatment for the Pelvic muscles strengthening and rehabilitating. Marc Beer has overseen completion of Series A project that did very well in the healthcare venture capital fund.
Recently Marc Beer introduced Series B project by raising $42 million to construct Boston-based healthcare center for women. They have employed a group of experts to research and establish new therapeutic and diagnostic treatments which are made with modern technology. Marc Beer has targeted more than 250 million women across the globe who suffer from Pelvic disorders precisely Urinary incontinence. Renovia company has advanced technologies which serve several purposes; Marc Beer has stated their partnership with Longwood company to share this technology as well as the skills to support the Series B foundation.
By the end of Series B, Marc Beer aims to have developed a digital program through which patients can access treatments guidelines and awareness about various diseases. This program will also provide knowledge and skills on treatments for pelvic disorders. Marc Beer understands that many women suffering from pelvic disorders fail to seek medical support since its very expensive he has therefore ensured that long-term healthcare services offered at Renovia re relatively low and affordable even to the middle-class income people. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer
In addition to the new Series B foundation, Marc Beer has announced the appointing of John A. Fallon a medical director to the company’s board of directors. He has also contributed to the establishment of REDUCE center to study and come up with the next generation treatment methods.